A Phase II Study of BEZ235 in Patients with Everolimus-resistant, Advanced Pancreatic Neuroendocrine Tumours.
Fazio N, Buzzoni R, Baudin E, Antonuzzo L, Hubner RA, Lahner H, DE Herder WW, Raderer M, Teulé A, Capdevila J, Libutti SK, Kulke MH, Shah M, Dey D, Turri S, Aimone P, Massacesi C, Verslype C.
Fazio N, et al. Among authors: baudin e.
Anticancer Res. 2016 Feb;36(2):713-9.
Anticancer Res. 2016.
PMID: 26851029
Free PMC article.
Clinical Trial.